ACE and SGLT2 inhibitors: the future for non‐diabetic and diabetic proteinuric renal disease

[1]  R. DeFronzo,et al.  Renal, metabolic and cardiovascular considerations of SGLT2 inhibition , 2017, Nature Reviews Nephrology.

[2]  V. Vallon,et al.  Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition , 2017, Diabetologia.

[3]  S. Moon,et al.  Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes , 2016, PloS one.

[4]  Ashutosh Kumar Singh,et al.  Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, The Lancet.

[5]  Ashutosh Kumar Singh,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[6]  M. Mahdavi-Mazdeh,et al.  Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. , 2016, The Lancet. Global health.

[7]  A. Tsapas,et al.  Empagliflozin , Cardiovascular Outcomes , and Mortality in Type 2 Diabetes , 2015 .

[8]  G. Remuzzi,et al.  Regression of Renal Disease by Angiotensin II Antagonism Is Caused by Regeneration of Kidney Vasculature. , 2016, Journal of the American Society of Nephrology.

[9]  S. Tang,et al.  Diabetic nephropathy: landmark clinical trials and tribulations. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  H. Parving,et al.  Early renin‐angiotensin system intervention is more beneficial than late intervention in delaying end‐stage renal disease in patients with type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[11]  H. Parving,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[12]  Bernadette A. Thomas,et al.  Maintenance Dialysis throughout the World in Years 1990 and 2010. , 2015, Journal of the American Society of Nephrology : JASN.

[13]  M. Tonelli,et al.  Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis , 2015, The Lancet.

[14]  E. Porrini,et al.  Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. , 2015, The lancet. Diabetes & endocrinology.

[15]  D. Cherney,et al.  Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy , 2015, Current opinion in nephrology and hypertension.

[16]  R. Gilbert.  Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? , 2014, Kidney international.

[17]  B. Hohenstein,et al.  The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. , 2014, American journal of physiology. Renal physiology.

[18]  G. Bakris,et al.  Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy , 2014, American Journal of Nephrology.

[19]  H. Yamada,et al.  Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice , 2014, PloS one.

[20]  A. Mithal,et al.  Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. , 2014, The lancet. Diabetes & endocrinology.

[21]  P. Nyirjesy,et al.  Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies , 2014, Current medical research and opinion.

[22]  C. Kovacs,et al.  Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial , 2014, Diabetes, obesity & metabolism.

[23]  H. Koepsell,et al.  SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. , 2014, American journal of physiology. Renal physiology.

[24]  L. Nicolle,et al.  Urinary Tract Infection in Randomized Phase III Studies of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor , 2014, Postgraduate medicine.

[25]  Lawrence A Leiter,et al.  Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial , 2013, The Lancet.

[26]  K. Johnsson,et al.  Urinary tract infections in patients with diabetes treated with dapagliflozin. , 2013, Journal of diabetes and its complications.

[27]  K. Johnsson,et al.  Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. , 2013, Journal of diabetes and its complications.

[28]  G. Bakris,et al.  Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease , 2013, Diabetes, obesity & metabolism.

[29]  C. Pollock,et al.  Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy? , 2013, PloS one.

[30]  G. Remuzzi,et al.  Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[31]  G. Remuzzi,et al.  Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes , 2012, Diabetes Care.

[32]  J. Luther.  Sodium intake, ACE inhibition, and progression to ESRD. , 2012, Journal of the American Society of Nephrology : JASN.

[33]  G. Remuzzi,et al.  The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. , 2011, Kidney international.

[34]  H. Parving,et al.  Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial , 2010, The Lancet.

[35]  L. Ruilope,et al.  Avosentan for overt diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[36]  A. Mitchell,et al.  Avosentan reduces albumin excretion in diabetics with macroalbuminuria. , 2009, Journal of the American Society of Nephrology : JASN.

[37]  P. Zamboli,et al.  Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[39]  G. Remuzzi,et al.  Role of remission clinics in the longitudinal treatment of CKD. , 2008, Journal of the American Society of Nephrology : JASN.

[40]  G. Remuzzi,et al.  Progression of chronic kidney disease: insights from animal models , 2006, Current opinion in nephrology and hypertension.

[41]  G. Remuzzi,et al.  ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. , 2006, Kidney international.

[42]  G. Remuzzi,et al.  Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. , 2006, The Journal of clinical investigation.

[43]  B. Brenner,et al.  Preventing microalbuminuria in type 2 diabetes. , 2005, The New England journal of medicine.

[44]  B. Brenner,et al.  Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy , 2004, Circulation.

[45]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[46]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[47]  G. Remuzzi,et al.  Progression, remission, regression of chronic renal diseases , 2001, The Lancet.

[48]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[49]  G. Remuzzi,et al.  In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. , 1999, Journal of the American Society of Nephrology : JASN.

[50]  G. Remuzzi,et al.  Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial , 1998, The Lancet.

[51]  P. Ruggenetu.  Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril : REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) , 1998 .

[52]  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) , 1997, Lancet.

[53]  N. Perico,et al.  Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. , 1994, Journal of the American Society of Nephrology : JASN.